KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery
作者： Jeong Won Lee , Jong Hoon Lee , Byoung Yong Shim , Sung Hwan Kim , Mi-Joo Chung
DOI: 10.1097/MD.0000000000001284
关键词: Oncology 、 KRAS 、 Radiation therapy 、 Colorectal cancer 、 Medicine 、 Chemoradiotherapy 、 Adenocarcinoma 、 Biopsy 、 Survival rate 、 Total mesorectal excision 、 Internal medicine 、 General Medicine
摘要: We evaluated the tumor response and survival according to KRAS oncogene status in locally advanced rectal cancer. One hundred patients with cancer (cT3-4N0-2M0) received preoperative radiation of 50.4 Gy 28 fractions 5-fluorouracil total mesorectal excision. Tumor DNA from each patient was obtained pretreatment biopsy tissues. A Kirsten rat sarcoma viral homolog (KRAS) mutation found 26 (26%) 100 patients. Downstaging (ypT0-2N0M0) rates after chemoradiotheray were not statistically different between wild-type mutant-type groups (30.8% vs 27.0%, P = 0.715, respectively). After a median follow-up time 34 months, there no significant difference 3-year relapse-free (82.2% 82.6%, P = 0.512) overall (94.7% 92.3%, P = 0.249) groups, respectively. The does influence radiotherapy who chemoradiotherapy curative surgery.
sci-hub.se 参考文章(33)
G. I Meling, P Laurent-Puig, B. J Iacopetta, R Glaesener, O. P. F Clausen, F Al-Mulla, W Giaretti, V. J Bubb, A. F. P. M de Goeij, G Gaudernack, T Ohkusa, P Quirke, A Rapallo, N Hawkins, R Rosell, T. O Rognum, S. N Andersen, R Smith, J Costa, R Ward, I Hoffmann, T Fujimori, D Cunningham, D Morton, C. T Croke, J Oates, X. F Sun, S Bell, P. A Clarke, S. T Wang, J Breivik, O Muller, A. R Norman, J. W Arends, M Pauly, D Dillon, H. J. N Andreyev, S. D Finkelstein, A. J Senagore, C. N Hall, K Wilkinson, N Lees, N. R Cruickshank, H. S Goh, D Snary, E Jullian, C Valavanis, L Losi, A Russo, H. M Rabes, J Piris, S Wadler, Y Ono, T Azuma, A Font, C Zietz, M Beranek, J. C Fox, S. A Halter, R Benamouzig, B. R Dix, H Zhang, C Faber, K Omura, V. E Pricolo, C Troungos, K Krtolica, J Benhattar, J. W. C Ho, N. Urosevic, T Lovig, D. P O'Donoghue, J. S Thebo, P De Angelis, J. Q Lee, J Young, Bazan, P Jandik, S Olschwang, S. T Yuen, T Walsh, S Malik, M Tanaka, Kirsten ras mutations in patients with colorectal cancer : the ‘RASCAL II’ study Faculty of Health; Institute of Health and Biomedical Innovation. ,vol. 85, pp. 692- 696 ,(2001)
Muschel Rj, Bakanauskas Vj, Stanbridge Ej, Bernhard Ej, Cerniglia Gj, McKenna Wg, Gupta Ak, Gupta S, Soto D, Direct Evidence for the Contribution of Activated N-ras and K-ras Oncogenes to Increased Intrinsic Radiation Resistance in Human Tumor Cell Lines Cancer Research. ,vol. 60, pp. 6597- 6600 ,(2000)
Y. Edden, S. D. Wexner, M. Berho, The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma. Colorectal Disease. ,vol. 14, pp. 555- 561 ,(2012) , 10.1111/J.1463-1318.2011.02697.X
George Theodoropoulos, W. E. Wise, A. Padmanabhan, B. A. Kerner, C. W. Taylor, P. S. Aguilar, K. S. Khanduja, T-Level Downstaging and Complete Pathologic Response After Preoperative Chemoradiation for Advanced Rectal Cancer Result in Decreased Recurrence and Improved Disease-Free Survival Diseases of The Colon & Rectum. ,vol. 45, pp. 895- 903 ,(2002) , 10.1007/S10350-004-6325-7
Jong Hoon Lee, Jun-Gi Kim, Seong Taek Oh, Myung Ah Lee, Hoo Geun Chun, Dae Yong Kim, Tae Hyun Kim, Sun Young Kim, Ji Yeon Baek, Ji Won Park, Jae Hwan Oh, Hee Chul Park, Doo Ho Choi, Young Suk Park, Hee Cheol Kim, Eui Kyu Chie, Hong Seok Jang, Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02) Radiotherapy and Oncology. ,vol. 110, pp. 150- 154 ,(2014) , 10.1016/J.RADONC.2013.11.013
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
C Bengala, S Bettelli, F Bertolini, G Sartori, A Fontana, N Malavasi, R Depenni, S Zironi, C Del Giovane, G Luppi, P F Conte, Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy British Journal of Cancer. ,vol. 103, pp. 1019- 1024 ,(2010) , 10.1038/SJ.BJC.6605853
Heather A. Jones, Stephen M. Hahn, Eric Bernhard, W. Gillies McKenna, Ras inhibitors and radiation therapy. Seminars in Radiation Oncology. ,vol. 11, pp. 328- 337 ,(2001) , 10.1053/SRAO.2001.26020
Jong Hoon Lee, Sung Hwan Kim, Hong Seok Jang, Hyuk Jun Chung, Seong Taek Oh, Doo Seok Lee, Jun-Gi Kim, Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population. International Journal of Colorectal Disease. ,vol. 28, pp. 511- 517 ,(2013) , 10.1007/S00384-012-1584-6
J. J. Malcorra-Azpiazu, H. I. Balda-Aguirre, J. C. Diaz-Chico, H. Hu, J. B. Wilson, B. B. Webber, F. Kutlar, A. Kutlar, T. H. J. Huisman, Hb Las Palms or α2β249(Cd8)Ser→Phe, a Mildly Unstable Hemiglobin Variant Hemoglobin. ,vol. 12, pp. 163- 170 ,(1988) , 10.3109/03630268808998022